Companies whose shares are expected to trade actively in today’s session are Research In Motion Limited (NASDAQ:RIMM) (TSE:RIM), Seacube Container Leasing ltd (NYSE:BOX), Caterpillar Inc. (NYSE:CAT), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Synovus Financial Corp. (NYSE:SNV) and Celsion Corporation (NASDAQ:CLSN).
Research In Motion Limited (NASDAQ:RIMM) (TSE:RIM): Shares of the BlackBerry maker surged 8 percent to $17.08 after its chief executive made comments about possible asset sales and licensing deal. Thorsten Heins, CEO of Research In Motion Limited (NASDAQ:RIMM) (TSE:RIM) said during an interview with Germany’s Die Welt newspaper that he could sell the company’s hardware unit or license the BlackBerry software.
Seacube Container Leasing Ltd (NYSE:BOX): The Park Ridge, N.J.-based company received an acquisition offer from one of Canada’s largest pension funds. The Canadian company has agreed to pay $23 per SeaCube share, a 13.3% premium over the company’s Friday closing price. The deal values Seacube Container Leasing Ltd (NYSE:BOX) at about $466 million. Shares rose 13.35 percent to $23 in early trading.
Caterpillar Inc. (NYSE:CAT): The machinery manufacturer said it has noticed some accounting malpractices at China’s ERA Mining Machinery Ltd, a firm Caterpillar Inc. (NYSE:CAT) acquired last year. An internal investigation revealed that several managers at the Chinese firm’s Siwei unit were involved in deliberate misconduct for the past many years before the acquisition. Shares of Caterpillar plunged 0.45 percent to $97.18 in early trading.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): The biopharmaceutical company said European authorities have raised questions about its weight loss drug Belviq. The regulators said the issues must be addressed orally and in writing before they will consider its approval in the European Union. A final decision on the drug is expected to be taken before June 2013. Shares dipped 8.70 percent to $8.92 in early trading.
Synovus Financial Corp. (NYSE:SNV): The financial services firm’s profits and revenues topped analysts’ estimates. The company said its earnings were helped by the sale of distressed assets and income-tax benefits related to the recapture of deferred tax-asset valuation allowance. Shares initially rose 2.6 percent, but dipped 1.48 percent to $2.67 in the early session.
Celsion Corporation (NASDAQ:CLSN): The cancer drug-development company said that it has signed a drug development agreement with China’s Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA:600267) for its liver cancer drug ThermoDox. Celsion Corporation (NASDAQ:CLSN) will receive $5 million from the Chinese company, while providing Zhejiang support for ThermoDox manufacturing program. The drug’s Phase III clinical trial results are expected by the end of this month. Shares jumped 5.57 percent to $$7.41 in the early session.
